Jula Inrig Sells 15,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 15,000 shares of the stock in a transaction that occurred on Wednesday, December 24th. The shares were sold at an average price of $42.00, for a total value of $630,000.00. Following the completion of the sale, the insider directly owned 88,787 shares of the company’s stock, valued at approximately $3,729,054. The trade was a 14.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Travere Therapeutics Stock Down 1.9%

TVTX traded down $0.76 during trading on Monday, reaching $38.88. 1,348,814 shares of the stock were exchanged, compared to its average volume of 1,736,032. The company has a debt-to-equity ratio of 4.23, a quick ratio of 2.71 and a current ratio of 2.75. The stock’s 50 day moving average price is $34.36 and its two-hundred day moving average price is $24.61. Travere Therapeutics, Inc. has a twelve month low of $12.91 and a twelve month high of $42.13. The stock has a market cap of $3.48 billion, a P/E ratio of -36.68 and a beta of 0.89.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, October 30th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.59. The company had revenue of $164.86 million during the quarter, compared to the consensus estimate of $106.09 million. Travere Therapeutics had a negative net margin of 20.32% and a negative return on equity of 178.68%. The company’s quarterly revenue was up 162.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.70) EPS. Equities analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on TVTX. Stifel Nicolaus increased their price target on Travere Therapeutics from $20.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, September 12th. Citigroup raised their target price on shares of Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company increased their price target on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an “overweight” rating in a report on Thursday, September 11th. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price objective on shares of Travere Therapeutics in a research report on Friday, November 28th. Thirteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $38.71.

Institutional Trading of Travere Therapeutics

A number of institutional investors have recently bought and sold shares of TVTX. First Horizon Corp bought a new position in shares of Travere Therapeutics during the third quarter worth approximately $36,000. Raymond James Financial Inc. acquired a new stake in Travere Therapeutics during the second quarter worth about $33,000. Headlands Technologies LLC bought a new position in Travere Therapeutics in the 2nd quarter valued at about $73,000. Quadrant Capital Group LLC acquired a new position in shares of Travere Therapeutics in the 3rd quarter valued at approximately $158,000. Finally, PharVision Advisers LLC bought a new stake in shares of Travere Therapeutics during the 3rd quarter worth approximately $210,000.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.